Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses.

Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA.

Arch Neurol. 2000 Mar;57(3):326-32.

PMID:
10714657
2.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

3.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

4.

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE.

N Engl J Med. 2005 Mar 31;352(13):1293-304. Epub 2005 Mar 7.

5.
6.

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.

Hayden M, Pignone M, Phillips C, Mulrow C.

Ann Intern Med. 2002 Jan 15;136(2):161-72.

PMID:
11790072
7.

[Acetylsalicylic acid in primary prevention of cardiovascular events; literature study].

Bredie SJ, Wollersheim HC, Verheugt FW, Thien T.

Ned Tijdschr Geneeskd. 2002 Jan 12;146(2):68-72. Dutch.

PMID:
11820060
8.

Prospective study of aspirin use and risk of stroke in women.

Iso H, Hennekens CH, Stampfer MJ, Rexrode KM, Colditz GA, Speizer FE, Willett WC, Manson JE.

Stroke. 1999 Sep;30(9):1764-71.

9.

An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease.

Hebert PR, Hennekens CH.

Arch Intern Med. 2000 Nov 13;160(20):3123-7.

PMID:
11074741
10.

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.

Hennekens CH, Sacks FM, Tonkin A, Jukema JW, Byington RP, Pitt B, Berry DA, Berry SM, Ford NF, Walker AJ, Natarajan K, Sheng-Lin C, Fiedorek FT, Belder R.

Arch Intern Med. 2004 Jan 12;164(1):40-4.

PMID:
14718320
11.

Low-dose aspirin for primary prevention of cardiovascular disease.

Bredie SJ, Wollersheim H, Verheugt FW, Thien T.

Semin Vasc Med. 2003 May;3(2):177-84.

PMID:
15199480
12.

An update on aspirin in the primary prevention of cardiovascular disease.

Eidelman RS, Hebert PR, Weisman SM, Hennekens CH.

Arch Intern Med. 2003 Sep 22;163(17):2006-10.

PMID:
14504112
13.

Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.

Reaume KT, Regal RE, Dorsch MP.

Ann Pharmacother. 2008 Apr;42(4):550-7. doi: 10.1345/aph.1K433. Epub 2008 Mar 4. Review.

PMID:
18319394
14.

[Primary prevention of cardiovascular diseases with acetylsalicylic acid].

Waltering A, Hemkens L, Florack C.

Dtsch Med Wochenschr. 2005 Dec 9;130(49):2847-52. Review. German.

PMID:
16317615
15.

Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.

Arjomand H, Cohen M, Ezekowitz MD.

J Invasive Cardiol. 2004 May;16(5):271-8. Review.

PMID:
15152137
16.

Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study.

Culebras A, Rotta-Escalante R, Vila J, Domínguez R, Abiusi G, Famulari A, Rey R, Bauso-Tosselli L, Gori H, Ferrari J, Reich E; TAPIRSS investigators.

Neurology. 2004 Apr 13;62(7):1073-80.

PMID:
15079004
17.

Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.

Matías-Guiu J, Ferro JM, Alvarez-Sabín J, Torres F, Jiménez MD, Lago A, Melo T; TACIP Investigators.

Stroke. 2003 Apr;34(4):840-8. Epub 2003 Mar 20.

18.

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.

Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators.

Am Heart J. 2006 Nov;152(5):967-73.

PMID:
17070169
19.

The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.

Hennekens CH, Schneider WR.

Expert Rev Cardiovasc Ther. 2008 Jan;6(1):95-107. Review.

PMID:
18095910
Items per page

Supplemental Content

Write to the Help Desk